ISFP & PA Workshop 2022

Lys Therapeutics announces to attend the 3rd Joint Meeting of the International Society of Fibrinolysis and Proteolysis and the Plasminogen Activation Workshop (“ISFP and PA Workshop”), happening this year in #Caen, 5-9 September 2022.

Dr. Manuel BLANC, Pr. Denis VIVIEN, Dr. Flavie Lesept, Dr. Fanny Potzeha, Dr. Jean-Baptiste BERTRAND and all Lys Therapeutics’ team is happy to meet you there.

💪 All together against Stroke and its dramatic consequences.

—
https://www.cyceron.fr/isfp/index.php?page=programme

—

With bb@c, Blood and Brain Caen normandie and CYCERON

#ISFP #Stroke #neurosciences #clinicaltrials #Research #PublicPrivatePartnership #Collaboration #deeptech #biotech #healthcare #lifesciences #CNS #brain #NeurologicalDiseases #NeurovascularDisorders #stroke #dementia #innovation #MedicalNeeds #LysTherapeutics #biotherapy #Glunomab #Glunozumab

Oral presentation – ISFP 2022

🔬🧠 “Lys Therapeutics, first-in-class biotherapies against neurological disorders”

 🎤 Dr. Manuel BLANC, CEO of Lys Therapeutics is presenting on September 7, 2022 during the 3rd Joint Meeting of the International Society of Fibrinolysis and Proteolysis and the Plasminogen Activation Workshop (“ISFP and PA Workshop”), new promising preclinical data with Lys Therapeutics’s lead candidate Glunomab / Glunozumab in ischemic stroke, used alone or in combination with #alteplase (#rtPA) or #tenecteplase (#TNK).

With bb@c, Blood and Brain Caen normandie and CYCERON

—

Link: https://isfp2022.exordo.com/programme/presentation/27

Scientific poster – ISFP 2022

🔬🧠 “Glunomab: A Novel Immunotherapy Preventing The Damaging Effects Of Both Endogenous And Recombinant tPA After Ischemic Stroke”

Lys Therapeutics is reinforcing its neurovascular business unit with updated preclinical data presented during the 3rd Joint Meeting of the International Society of Fibrinolysis and Proteolysis and the Plasminogen Activation Workshop (“ISFP and PA Workshop”) for its lead candidate Glunomab in ischemic stroke including with diabetes, an important comorbidity among stroke patients, when administered either alone or in combination with #alteplase (#rtPA) or N-acetylcysteine (#NAC), two known thrombolytics against fibrin-rich or platelet-rich blood clots, respectively.

Dr. Manuel BLANC, Pr. Denis VIVIEN, Dr. Flavie Lesept, Dr. Fanny Potzeha and Florent Lebrun are happy to meet you there.

With ETAP-Lab – Preclinical CRO , bb@c, Blood and Brain Caen normandie and CYCERON.

—

Link: https://isfp2022.exordo.com/programme/presentation/48